emicizumab

Innovative Thrombin-Responsive AutoRegulated FVIII-Mimetic Antibodies for Safer Hemophilia A Therapy

A novel thrombin-cleavable FVIII-mimetic antibody enables dynamic, on-demand control of coagulation, reducing adverse thrombotic risk while maintaining efficacy in hemophilia A treatment.